Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback